Меню
Набор скоро начнётся NCT07690007

Combined Misoprostol and Cervical Balloon vs Misoprostol Alone for Induction on the First Day in Primiparas

Фаза IV С лечением Primiparous Women

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Misoprostol, Misoprostol plus Cervical Balloon.
Кому может быть актуально
Состояния в реестре: Primiparous Women. Базовые параметры: 20 лет — 45 лет · Женщины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Список центров уточняется — проверьте первичный протокол.
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Efficacy of Intravaginal Misoprostol Combined With Cervical Balloon Versus Misoprostol Alone for Induction of Labor on the First Day in Primiparous Women: A Randomized Controlled Trial

Обзор

Misoprostol (a prostaglandin E1 analog) is commonly used for cervical ripening and labor induction via vaginal administration. The cervical balloon is another commonly used method that provides mechanical cervical dilation. Both methods are low-cost and widely available. Some meta-analyses have suggested that combined use may shorten the duration of labor, reduce the frequency of tachysystole, and lower NICU admission rates without increasing the risk of cesarean section. However, existing studies are heterogeneous and lack data from Asian populations. This study is being done to see whether combining two common methods of labor induction-misoprostol (a medicine placed in the vagina) and a cervical balloon (placed in the cervix) on the first day of induction-can shorten the time from the start of induction to delivery in first-time mothers during pregnancy . Participants will be randomly assigned to one of two groups: one group will receive misoprostol alone (standard care) on the first day of induction, and the other group will receive misoprostol plus a cervical balloon on the first day of induction. The main outcome measured is the time from the start of induction to delivery. The study will also look at safety outcomes, including the rate of cesarean section, maternal complications, and newborn outcomes.

Подробное описание

This is a single-center, randomized, open-label, superiority randomized controlled trial. Participants will be randomly assigned in a 1:1 ratio to either the intervention group (misoprostol plus cervical balloon on the first day of induction) or the control group (misoprostol alone on the first day of induction).

IPRIMARY OUTCOME:

Time from initiation of labor induction to delivery (hours).

SECONDARY OUTCOMES:

Time from induction to amniotomy (min), time from induction to spontaneous membrane rupture (h), time from induction to onset of labor (min), duration of balloon use (min), duration of oxytocin use (min), duration of latent phase (h), duration of first and second stages of labor (min), mode of delivery, degree of perineal laceration, indications for forceps/episiotomy/cesarean section, fetal distress, intrauterine infection, neonatal outcomes (birth weight, Apgar score, umbilical artery pH/BE, NICU admission), and maternal hemoglobin difference before and after delivery. Safety outcomes include placental abruption, septic shock, and severe postpartum hemorrhage.

SAMPLE SIZE:

Based on historical data from 90 primiparous women at Peking University First Hospital (June 2025), the mean induction-to-delivery interval was 39.07 ± 19.92 hours. Assuming an 8-hour reduction in the intervention group, with a two-sided alpha of 0.05, power of 80%, and a 10% dropout rate, each group requires 110 participants (total 220).

STATISTICAL ANALYSIS:

Continuous variables will be compared using t-test or Mann-Whitney U test as appropriate. Categorical variables will be compared using chi-square or Fisher's exact test. Multivariable linear regression and logistic regression will be used for adjusted analyses. Subgroup analyses will be performed by type of hyperglycemia, age, BMI, and baseline Bishop score.

ETHICS AND REGISTRATION:

This study has been approved by the Biomedical Research Ethics Committee of Peking University First Hospital (Approval No. 2025R0393-0002, dated September 25, 2025). The study is registered on ClinicalTrials.gov.

STUDY PERIOD:

June 2026 to December 2026.

Вмешательства

  • Препарат Misoprostol
    25 μg misoprostol tablet placed in the posterior vaginal fornix for cervical ripening and labor induction on the first day. May be repeated up to 3-4 times based on uterine contraction response (monitored every 2-4 hours).
  • Устройство Misoprostol plus Cervical Balloon
    A Cervical balloon with 80 mL sterile water inflation placed intracervically for mechanical cervical dilation. The balloon is left in place for up to 12-24 hours or until spontaneous expulsion.

Первичные конечные точки

  • Time from initiation of labor induction to delivery [Срок оценки: Time from initiation of induction measures on the first day of induction to delivery (control group: time of first misoprostol placement; intervention group: time of cervical balloon and misoprostol placement).]
Вторичные конечные точки (12)
  • Time from Induction to Amniotomy [Срок оценки: From start of induction to amniotomy]
  • Time from Induction to Spontaneous Membrane Rupture [Срок оценки: From start of induction to spontaneous rupture]
  • Time from Induction to Onset of Labor [Срок оценки: From start of induction to onset of labor]
  • Duration of Balloon Use [Срок оценки: From balloon insertion to removal, assessed during the induction period (up to 24 hours).]
  • Duration of Oxytocin Use [Срок оценки: From start to stop of oxytocin infusion, assessed during labor]
  • Duration of Latent Phase of Labor [Срок оценки: From onset of labor to active phase, assessed during labor]
  • Duration of First and Second Stages of Labor [Срок оценки: From full dilation to delivery, assessed during the second stage]
  • Mode of Delivery [Срок оценки: At the time of delivery.]
  • Degree of Perineal Laceration [Срок оценки: Immediately after vaginal delivery.]
  • Indications for Forceps/Episiotomy/Cesarean Section [Срок оценки: At the time of the operative intervention (during labor/delivery).]
  • Fetal Distress [Срок оценки: During labor, assessed up to delivery.]
  • Intrauterine Infection [Срок оценки: During labor and up to 48 hours postpartum.]

Критерии участия

Критерии включения

  • Age 20-45 years at delivery
  • Singleton pregnancy
  • Primiparous
  • Cephalic presentation
  • Cervical Bishop score ≤ 5
  • No history of stillbirth

Критерии исключения

  • Multiple pregnancy
  • Contraindications to vaginal delivery
  • Mental disorders (depression or anxiety)
  • Preterm labor (< 37 weeks)
  • Intrauterine fetal death
  • Previous uterine surgery
  • Premature rupture of membranes
  • Abnormal fetal heart rate tracing

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07690007 · 2025R0393-0002

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗